1.	hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Phase: Phase II Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI, Other Protocol IDs: ANBL0322, CDR0000360723, COG-ANBL0322, NCI-2012-02583, NCT00082758
2.	Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: H2007-0087, CO05601, NCT00590824
3.	Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000426431, WCCC-CO-04601, NCI-6304, WCCC-H-2004-0396, 6304, NCT00109863
4.	Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 12 months to 30 years Sponsor: NCI, Other Protocol IDs: ANBL1021, NCI-2011-02672, CDR0000698589, U10CA098543, COG-ANBL1021, NCT01334515
5.	Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000066870, COG-ADVL0018, NCT00003750